Innovene Therapeutics

Innovene Therapeutics is dedicated to advancing biotechnology research and pioneering innovative solutions in the pharmaceutical sector. Specializing in the development of antiviral polyphenol-based therapeutic compounds, Innovene Therapeutics focuses on treating persistent HPV infections caused by the Human Papillomavirus. Their lead drug, INV-015, represents a significant advancement in the field, utilizing a proprietary formulation designed for the treatment of infections with high-risk HPV subtypes.

With a multidisciplinary team that combines clinical expertise, R&D competence, and business acumen, Innovene Therapeutics ensures its solutions are effectively tailored to meet patient needs and are successfully introduced into the market. Strategic drug screening has yielded a synergistic mixture of compounds that directly inhibit viral replication and modulate the patient’s immune system to clear HPV-infected cells. Innovene Therapeutics is committed to delivering scientifically advanced and commercially viable treatments.

Innovene Therapeutics is actively shaping the future of antiviral therapies. We invite the management team at Innovene Therapeutics to enhance your company's presence on our platform with a customized company showcase and detailed product listings. This will provide an excellent opportunity to further highlight your innovations and connect with a broader audience.